临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 1019206-88-2

Regorafenib (BAY-734506) Monohydrate

中文名称: 瑞格非尼水合物
CAS号:1019206-88-2
分子式: C21H15ClF4N4O3.H2O 分子量: 500.83
产品形式: monohydrate
研发状态: Completed
研发用途: Colorectal Neoplasms
研究机构: Bayer
研发日期: January 31 2018
研发阶段: --
Regorafenib (BAY-734506, Fluoro-sorafenib, Resihance, Stivarga, regorafaenib monohydrate) Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM for VEGFR1, murine VEGFR2, murine VEGFR3, PDGFR-β, Kit (c-Kit), RET (c-RET), RAF-1, B-RAF and B-RAF(V600E) respectively.

CAS: 1018899-04-1

Sotagliflozin (LX4211)

中文名称: 索格列净
CAS号:1018899-04-1
分子式: C21H25ClO5S 分子量: 424.94
产品形式: free base
研发状态: Not yet recruiting
研发用途: Nephropathy; Diabetic Nephropathies; Diabetes Mellitus Type 1; Albuminuria; Diabetic Complications Renal; Diabetic Complications Cardiovascular; Hypoxia
研究机构: Steno Diabetes Center Copenhagen; Juvenile Diabetes Research Foundation; King''s College London; Glostrup University Hospital Copenhagen
研发日期: Aug-24
研发阶段: Phase 4
Sotagliflozin (LX4211, LP-802034) is an oral dual SGLT1/SGLT2 inhibitor with IC50 of 36 nM and 1.8 nM, respectively. Phase 3.

CAS: 1018673-42-1

GSK3117391

CAS号:1018673-42-1
分子式: C22H33N3O4 分子量: 403.52
产品形式: Free Base
研发状态: Terminated
研发用途: Arthritis Rheumatoid
研究机构: GlaxoSmithKline
研发日期: December 27 2016
研发阶段: Phase 2
GSK3117391 (GSK3117391A, HDAC-IN-3) is a potent histone deacetylase (HDAC) inhibitor.

CAS: 1015787-98-0

Gefapixant

CAS号:1015787-98-0
分子式: C14H19N5O4S 分子量: 353.40
产品形式: free base
研发状态: Recruiting
研发用途: Chronic Cough
研究机构: Stuart Mazzone; Merck Sharp & Dohme LLC; Melbourne Health; Monash University; University of Melbourne
研发日期: January 1 2024
研发阶段: Early Phase 1
Gefapixant (AF-219, MK-7264, R1646, RG-1646, RO 4926219) is an orally active small molecule antagonist of human P2X3 receptor with IC50 of about 30 nM, 100–250 nM for recombinant hP2X3 homotrimers and hP2X2/3 heterotrimeric receptors, respectively. Gefapixant has shown promise for the treatment of refractory and unexplained chronic cough.

CAS: 1015474-32-4

Avadomide (CC-122)

中文名称:3-(5-氨基-2-甲基-4-氧喹唑啉-3(4H)-基)哌啶-2,6-二酮
CAS号:1015474-32-4
分子式: C14H14N4O3 分子量: 286.29
产品形式: Free Base
研发状态: Active not recruiting
研发用途: Non-Hodgkin Lymphoma
研究机构: Bristol-Myers Squibb
研发日期: April 11 2023
研发阶段: Phase 1
Avadomide (CC-122), a new chemical entity termed pleiotropic pathway modifier, is a novel agent for Diffuse large B-cell lymphoma(DLBCL) with antitumor and immunomodulatory activity. Its molecular target is the protein cereblon (CRBN), a substrate receptor of the cullin ring E3 ubiquitin ligase complex CRL4CRBN.

CAS: 1013920-15-4

Vorolanib

中文名称:伏罗尼布
CAS号:1013920-15-4
分子式: C23H26FN5O3 分子量: 439.40
产品形式: Free Base
研发状态: Completed
研发用途: Advanced Malignant Solid Tumors
研究机构: AnewPharma
研发日期: December 19 2019
研发阶段: Phase 1
Vorolanib (X-82,CM082) is an oral, multikinase, dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) with antiangiogenic and antineoplastic activities.